U.S. flag

An official website of the United States government

Branded Prescription Drug Fee Program Manufacturer Resources

Based on the Branded Prescription Drug Fee Program (BPD) disputes received through Internal Revenue Service (IRS) to date, the following information is offered for those manufacturers that seek review of BPD disputes of Medicaid sales amounts:

  1. Begin Reviewing State Utilization Data Early: Manufacturers should email states and copy Medicaid (MedicaidBPD@cms.hhs.gov) regarding issues with the current BPD year’s utilization data (i.e., 2022) as soon as they become aware of them. Don’t wait until the IRS opens the current year’s BPD disputes to report utilization overstatements and understatements to states and the Centers for Medicare & Medicaid Services (CMS) for the first time.
  2. Use Appropriate Supporting Documentation to Dispute: Manufacturers should use state-sourced data to dispute utilization numbers from states, where the dispute is that the Medicaid sales amount was calculated as too high or too low based on the state’s reported utilization. For example, supporting documentation such as state invoices or emails exchanged between manufacturers and states showing agreement on unit changes would be considered responsive BPD dispute data. A manufacturer’s Reconciliation of State Invoice (ROSI) and Prior Quarter Adjustment Statement (PQAS) could also be considered responsive if it contains a clear state response indicating agreement with the manufacturer. Supporting documentation such as manufacturer data unrelated to rebates would generally not be considered responsive for purposes of defending a dispute. Further, if Center for Medicaid and CHIP Services (CMCS) receives disputes from the same manufacturer that include instances of both over and underpayment, responsive supporting documentation should be provided for both instances.
  3. Contact CMS Regarding Unit Rebate Amount (URA) inaccuracies as soon as possible: Manufacturers should contact CMS as soon as possible if they believe a URA calculated by CMS is inaccurate. We request that manufacturers do not wait until the IRS opens the current year’s BPD dispute window to report potential URA issues to CMS for the first time. For line extension drugs, a manufacturer’s supporting documentation should include the ROSI/PQAS with the labeler-calculated URA, along with confirmation from several states that the labeler-reported URA is what was paid.
  4. Be Proactive in Addressing Unit of Measure Issues: Manufacturers should communicate with states about drugs that require unit of measure conversions to facilitate correct rebate billing. If a manufacturer submits a BPD dispute on a national drug code (NDC) that many/all states bill incorrectly, but the manufacturer has allowed the states’ incorrect units to remain publicly posted on Medicaid.gov without ever notifying CMS of the problem, it is unlikely that Medicaid will be able to fix this during the IRS’s BPD dispute time frame. As a result, manufacturers are strongly encouraged to be proactive and contact CMCS in a timely manner if a state will not fix their data or respond to repeated efforts to correct a unit of measure issue. Further, should a manufacturer dispute a Medicaid sales amount on the basis of a unit of measure discrepancy, the manufacturer is encouraged to include documentation of any attempts at preventing such disputes with states.
  5. Consult with All Appropriate Manufacturer Contacts: If the Medicaid Drug Rebate Program (MDRP) Technical Contact for the labeler code is not also the BPD contact engaging in disputes, manufacturers should ensure that disputes are appropriately based on rebate data. Further, communication between both contacts can help to ensure that the rebate data is understood by the manufacturer’s BPD contact.
  6. Use Proper Dispute Format: Manufacturers should include one unit total for Fee for Service (FFS) and one unit total for Managed Care Organization (MCO) per NDC per quarter per state for all federal Medicaid disputes. Dispute submissions should not include multiple unit totals for the same NDC/quarter from separate state invoices (e.g., one unit total for FFS physician-administered drugs and one unit total for retail pharmacy FFS drugs for the same state and NDC/quarter).
  7. Report Partial Unit Agreements to CMS on a Timely Basis: In the event a manufacturer and state have agreed to a partial reduction or adjustment in the disputed units of an NDC for a quarter(s), the manufacturer should provide information to the state and to CMS on the partial agreement if they see that the state hasn’t transmitted that agreed-upon change in utilization data to CMS Medicaid. Manufacturers shouldn’t wait until the IRS opens the current year’s BPD dispute window to report such expected utilization changes.

Questions regarding the BPD program for Medicaid should be sent to MedicaidBPD@cms.hhs.gov

Disclaimer: Please note that the information provided on this web page does not bind or obligate the Centers for Medicare and Medicaid Services (CMS). The statements included on this web page are intended to provide information on the Medicaid Branded Prescription Drug Fee Program (BPD) and do not in any way revise or modify the requirements set forth in Section 1927 of the Act, the national drug rebate agreement (NDRA), subsequent program releases, or regulations. 

Page last updated on September 21, 2023